Announcement on Shareholding Reduction Plan of Shareholders
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Shareholding Reduction Plan of Shareholders
Filed with SSE ·
6ix hasn’t read this filing yet.
Shanghai Junshi Biosciences Co., Ltd. on 6ix
Earlier from Shanghai Junshi Biosciences
- Announcement on Increasing Implementation Subject of Sub-Projects of Some Investment Projects Financed by Raised Funds
- Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
- Announcement on Expiration of Shareholding Reduction Plan for Shareholders with Over 5% Shares and Non-Execution of Shareholding Reduction
- Announcement on Result of Share Increase by the Controlling Shareholder and Actual Controller & Chairman, and the Equity Change Reaching the 1% Scale
- Announcement on Convening the 2025 Annual Performance Briefing
Later from Shanghai Junshi Biosciences
- Announcement on Resolutions of the 19th Meeting of the 4th Board of Directors
- Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
- Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
- Notice on Convening the 2025 Annual General Meeting
Follow Shanghai Junshi Biosciences into a list and get an email when it puts out news.
Follow Shanghai Junshi Biosciences